U.S. FDA approves ScPharmaceuticals' heart failure therapy (updated)
10/10/2022 13:32
(Adds details on drug launch, background)
Oct 10 (Reuters) - The U.S. Food and Drug Administration
on Monday approved ScPharmaceuticals Inc's SCPH.O therapy to
treat congestion of heart due to fluid overload among patients
with heart failure.
The approval marks the end of a long path to the market for
the therapy, Furoscix, after the regulator rejected it twice.
The drug is delivered via an on-body infusor. Heart failure
is a long-term condition in which the heart cannot pump enough
blood to meet the body's needs all the time.
There are more than seven million heart failure patients in
the United States, and they will now be able to self-administer
the treatment at home, Chief Executive John Tucker said in a
statement.
Shares of the company, which expects to launch the treatment
in the first quarter of 2023, rose 2.2% to $5.1 in premarket
trading.
(Reporting by Manas Mishra and Khushi Mandowara in Bengaluru;
Editing by Arun Koyyur)
((Manas.Mishra@thomsonreuters.com;
www.twitter.com/Manaswrites15;))